Effects of PACAP and VIP on adrenal progesterone release.
Baranowska
B
B
Department of Neuroendocrinology, Medical Centre of Postgraduate Education, Warsaw, Poland.
Wasilewska-Dziubińska
E
E
Radzikowska
M
M
Płlonowski
A
A
Roguski
K
K
Krawczyk
E
E
Kawalec
M
M
D000311:Adrenal Glands / Q000187:drug effects / Q000378:metabolism*; D000526:Alprenolol / Q000494:pharmacology; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D002478:Cells, Cultured; D016895:Culture Media, Serum-Free; D005260:Female; D006107:Granulosa Cells / Q000187:drug effects / Q000378:metabolism*; D018738:Hexamethonium / Q000494:pharmacology; D007044:Hysterectomy; D009271:Naltrexone / Q000494:pharmacology; D009479:Neuropeptides / Q000494:pharmacology*; D018377:Neurotransmitter Agents / Q000494:pharmacology; D010052:Ovariectomy; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D011374:Progesterone / Q000096:biosynthesis* / Q000097:blood / Q000378:metabolism; D051381:Rats; D011921:Rats, Inbred WKY; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology*
C495403:Adcyap1 protein, rat; D016895:Culture Media, Serum-Free; D009479:Neuropeptides; D018377:Neurotransmitter Agents; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D014660:Vasoactive Intestinal Peptide; D018738:Hexamethonium; D011374:Progesterone; D009271:Naltrexone; D001285:Atropine; D000526:Alprenolol